---
title: "Londons Junior Market Suffers Fresh Blow as Biotech Firm Exits"
publisher: "Stockmark.IT"
author: "Stockmark.IT Website"
published: "2024-08-31T11:06:36+00:00"
modified: "2024-08-31T11:06:36+00:00"
date: 2024-08-31
canonical: "https://stockmark.it/londons-junior-market-suffers-fresh-blow-as-biotech-firm-exits/"
category: "Stockmarket"
categories: ["Stockmarket", "Stockmarket News"]
image: "https://i0.wp.com/stockmark.it/wp-content/uploads/2023/01/stock-market.jpg?fit=1200%2C800&quality=89&ssl=1"
format: "news"
language: "en-GB"
---

# Londons Junior Market Suffers Fresh Blow as Biotech Firm Exits

**Published:** August 31, 2024
**Author:** Stockmark.IT Website
**Categories:** Stockmarket, Stockmarket News
**Featured image:** ![A digital screen displays a Bitcoin to US Dollar trading chart with candlestick patterns, price indicators, and buy/sell options, showing BTC/USD price at $9,203.20. @ stockmark.it](https://i0.wp.com/stockmark.it/wp-content/uploads/2023/01/stock-market.jpg?fit=1200%2C800&quality=89&ssl=1)

---

The Alternative Investment Market (AIM) in London has faced another setback with the announcement from Reneuron, a biotechnology company, regarding its departure from the junior stock exchange. Once valued at over £500 million, Reneuron has entered administration after struggling to secure sufficient working capital to continue trading on AIM. The company cited limited cash availability and unfavorable terms from potential investors as reasons for not pursuing a “highly dilutive” fundraising effort.

Reneuron’s shares, which traded above 300p in 2019, have been suspended for over six months and are set to be delisted from the exchange next week. This exit is part of a growing trend of companies leaving AIM, particularly in the biotech sector, where many British firms have expressed frustration over the challenges of raising capital on the junior market. As a result, some are opting for private ownership or seeking listings in other markets.

The Welsh government, which had invested £5 million in Reneuron and provided a £7.8 million grant package to support its relocation to Wales, now faces uncertainty regarding the future of its investment. Reneuron’s administrators have indicated they will continue discussions with creditors to assess the company’s solvency, with options for the firm’s future potentially including a “continuation as a private company.”

This situation underscores the ongoing challenges faced by AIM and raises concerns about its capacity to support growth-stage companies, especially in the biotechnology sector. As more firms choose to delist or move to other markets, the viability and role of London’s junior market are increasingly being questioned.

---

**Original URL:** https://stockmark.it/londons-junior-market-suffers-fresh-blow-as-biotech-firm-exits/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*